All content on this page is intended for educational and research purposes only. AOD-9604 is not approved by the FDA for human use and is sold exclusively as a research compound.
What Is AOD-9604?
AOD-9604 is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, specifically amino acids 176 through 191, with a stabilizing tyrosine substitution at the N-terminus. The name AOD stands for Anti-Obesity Drug, reflecting its original development purpose. It was designed in the 1990s by Metabolic Pharmaceuticals Ltd. in Australia with a specific research goal: to isolate the lipolytic properties of human growth hormone in a shorter, more targeted fragment, while avoiding the broader systemic effects of the full hormone.
What makes AOD-9604 particularly interesting as a research subject is what it does not do. Unlike full-length human growth hormone, AOD-9604 does not activate the growth hormone receptor, does not elevate IGF-1 levels, and does not affect glucose metabolism or insulin sensitivity. This selectivity gives researchers a cleaner experimental tool for studying fat metabolism pathways in isolation, without the confounding variables that come with administering full-length growth hormone.
AOD-9604 has one of the more substantial human clinical trial records among research peptides, having completed six randomized, double-blind, placebo-controlled trials involving over 900 participants before development was discontinued in 2007.
Origin and Development History
Research into growth hormone fragments began from the observation that different regions of the growth hormone molecule appeared to produce different biological effects. The C-terminal region, encompassing amino acids 176 to 191, was identified as the segment most associated with lipolytic activity. The hypothesis driving early AOD-9604 research was that this fragment could retain the fat-metabolizing properties of the parent hormone without triggering growth-promoting or diabetogenic effects.
Metabolic Pharmaceuticals Ltd. advanced AOD-9604 through a full clinical development program, reaching Phase IIb trials. Phase IIa data showed promising signals for weight reduction. The pivotal Phase IIb trial, however, failed to demonstrate statistically significant weight loss sufficient to support commercial development, and the program was discontinued. The compound has since remained an active subject of preclinical and mechanistic research, particularly in the areas of adipose metabolism and cartilage biology.
Mechanism of Action: What the Research Shows
AOD-9604’s biological activity in preclinical models operates through two complementary mechanisms that together distinguish it from other compounds studied in metabolic research.
1. Beta-3 Adrenergic Receptor Activation and Lipolysis
The primary mechanism documented in preclinical research involves AOD-9604’s activation of beta-3 adrenergic receptors on adipocytes, the cells that store fat. This receptor activation triggers hormone-sensitive lipase (HSL), the enzyme responsible for breaking down stored triglycerides into free fatty acids and glycerol, which can then be mobilized for energy use. This process is lipolysis.
The importance of the beta-3 adrenergic receptor pathway to AOD-9604’s effects was confirmed in a mechanistically significant animal study. When researchers used genetically modified mice lacking beta-3 adrenergic receptors, chronic AOD-9604 treatment produced no changes in weight or lipolytic activity, directly confirming that this receptor pathway is necessary for the peptide’s observed metabolic effects.
A foundational study published in 2000, Metabolic Studies of a Synthetic Lipolytic Domain (AOD9604) of Human Growth Hormone, demonstrated that AOD-9604 reduced body weight in genetically obese animal models by approximately 50% compared to controls over the study period, with no observed impact on blood glucose or insulin sensitivity. This study established the basic metabolic profile that subsequent research has continued to examine.
2. Inhibition of Lipogenesis
Alongside its lipolytic activity, AOD-9604 has been shown in preclinical models to suppress lipogenesis, the formation of new fat from dietary substrates. This occurs through inhibition of lipogenic enzymes including fatty acid synthase and acetyl-CoA carboxylase. The dual action of promoting fat breakdown while simultaneously reducing new fat formation is a combination that has made AOD-9604 a useful tool in metabolic research contexts where investigators want to study both sides of the fat balance equation.
3. Receptor Independence from Growth Hormone Pathways
A central finding across multiple AOD-9604 studies is its functional independence from the conventional growth hormone receptor pathway. Full-length human growth hormone stimulates lipolysis but also raises blood glucose, elevates IGF-1, and can produce side effects including fluid retention and joint discomfort. AOD-9604 consistently fails to activate the GH receptor in the same way, does not raise IGF-1 levels, and has not produced these associated effects in preclinical models or human trials. This makes it a cleaner tool for isolating and studying adipose metabolism pathways without these confounders.
AOD-9604 in Human Clinical Trials
AOD-9604 has a more substantial human data record than most research peptides. Six randomized, double-blind, placebo-controlled trials were completed across its development program, spanning both oral and intravenous administration routes at various dosing levels including 0.25 mg, 0.5 mg, and 1.0 mg daily.
A frequently cited 12-week randomized trial found that subjects receiving AOD-9604 at 1 mg per day lost an average of 2.6 kg compared to 0.8 kg in the placebo group. This represented a statistically meaningful early signal, though subsequent larger trials did not consistently replicate this effect at commercially viable magnitudes.
The safety profile across these trials was notably clean. Multiple studies confirmed no effect on blood glucose, no elevation of IGF-1, and no suppression of endogenous growth hormone production. These findings contributed to AOD-9604 receiving GRAS (Generally Recognized as Safe) designation in the context of food use, an unusual distinction for a research peptide that reflects the depth of its human safety data relative to most compounds in this category.
The development program was ultimately discontinued after the pivotal Phase IIb trial failed to demonstrate weight loss of sufficient magnitude for regulatory approval as an obesity drug. The question the trials did not fully answer, and which subsequent research continues to explore, is whether the compound has meaningful applications in other research contexts beyond its original obesity focus.
AOD-9604 in Cartilage and Joint Research
One of the more unexpected areas of AOD-9604 research has emerged in cartilage biology and joint repair models, a direction not anticipated in the compound’s original metabolic development program.
A 2015 study published in PubMed (PMID: 26275694) by Kwon DR and Park GY examined the effect of intra-articular injection of AOD-9604 with and without hyaluronic acid in a collagenase-induced knee osteoarthritis rabbit model. The study found that intra-articular AOD-9604 injections enhanced cartilage regeneration compared to controls. The combined treatment of AOD-9604 and hyaluronic acid produced greater improvement in cartilage structure than either compound administered alone.
The mechanism by which AOD-9604 may influence cartilage tissue is not yet fully established. Current hypotheses center on its potential to reduce the inflammatory signaling cascade that accelerates cartilage matrix breakdown in osteoarthritis models, as distinct from direct tissue regeneration. Researchers have distinguished between chondroprotection, the slowing of cartilage degradation, and chondrogenesis, the active rebuilding of cartilage tissue. Available preclinical data most strongly supports the former, though research in this area is ongoing.
No Phase III clinical trials have evaluated AOD-9604 for osteoarthritis or cartilage applications in humans. All joint-related findings to date come from animal models.
Regulatory Status in 2026
AOD-9604’s regulatory situation has shifted recently. The compound was previously nominated to the FDA’s Category 2 bulk drug substance list, which would have restricted its preparation by compounding pharmacies. As of April 2026, that nomination has been withdrawn from the Category 2 list. This does not constitute FDA approval for human therapeutic use. AOD-9604 remains unapproved for any human or veterinary application by the FDA or any other major regulatory agency.
WADA lists growth hormone fragments including AOD-9604 (referenced as hGH 176-191) on its prohibited substances list under the category of peptide hormones, growth factors, and related substances. Researchers working with athletes or in sports science contexts should note this classification.
What We Don’t Know Yet
AOD-9604 has more human data than most research peptides, which makes it easier to define what the evidence does and does not support.
The clinical trial program was powered to detect weight loss in obese populations. It was not designed to evaluate AOD-9604 in the cartilage, joint, or musculoskeletal contexts that have since emerged as areas of preclinical interest. Human data for these applications does not yet exist.
The 12-week trial result showing 2.6 kg loss versus 0.8 kg placebo is real but modest, and it was not consistently replicated in larger trials. Researchers evaluating AOD-9604 in metabolic contexts should work within a realistic understanding of what the human evidence shows.
The animal-to-human translation gap applies here as it does across all peptide research. Significant fat reduction in obese rodent models did not translate to commercially viable weight loss in humans. Whether the cartilage findings from rabbit OA models will translate differently remains an open research question.
Research Formats Available
For researchers sourcing AOD-9604 for laboratory use, the compound is available in lyophilized powder form requiring reconstitution. Purity verification through HPLC and mass spectrometry, along with batch-specific Certificates of Analysis, should be confirmed before use in any research context.
Alpha Peps supplies research-grade AOD-9604 (10mg) with third-party COA verification. All products are sold exclusively for research purposes and are not intended for human consumption.
Frequently Asked Questions
What is AOD-9604 derived from?
AOD-9604 is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, specifically amino acids 176 through 191, with a stabilizing tyrosine substitution at the N-terminus. It is produced synthetically and is not extracted from biological material.
How does AOD-9604 differ from human growth hormone?
AOD-9604 does not activate the growth hormone receptor, does not elevate IGF-1 levels, and does not affect glucose metabolism or insulin sensitivity. Full-length human growth hormone produces all of these effects. AOD-9604 was specifically designed to isolate the lipolytic properties of growth hormone while avoiding its broader systemic effects.
How many human trials have been conducted on AOD-9604?
Six randomized, double-blind, placebo-controlled trials were completed involving over 900 participants. The trials evaluated oral and intravenous administration at multiple dose levels. Development was discontinued after the pivotal Phase IIb trial did not demonstrate sufficient weight loss for regulatory approval.
What tissues has AOD-9604 been studied in?
AOD-9604 has been studied primarily in adipose tissue in the context of fat metabolism research, and more recently in cartilage and joint tissue through osteoarthritis animal models. The metabolic research has included human trials. The cartilage research remains at the preclinical stage.
Is AOD-9604 approved for human use?
No. AOD-9604 is not approved for human therapeutic use by the FDA or any other major regulatory agency. It is sold exclusively as a research compound for laboratory use.
Where can I source AOD-9604 for research purposes?
Alpha Peps supplies research-grade AOD-9604 (10mg) with batch-specific third-party COA verification and 99%+ purity. All products are for laboratory research use only.
This article is for informational and research purposes only. Nothing on this page constitutes medical advice. AOD-9604 is not approved for human use and should only be handled by qualified researchers in appropriate laboratory settings.
